Rapid designation of orphan drugs status to potential formulations in recent years is slated to broaden expansion prospects
Rapid designation of orphan drugs status to potential formulations in recent years is slated to broaden expansion prospects
Fact.MR, Rockville MD: Fact.MR’s ongoing research study on the global eosinophilic granulomatosis market forecasts an optimistic trajectory through 2021. Growth is expected to build upon gains accrued in FY 2020-21, with extensive deployment to treat respiratory disorders patients for reducing possible complications in case of a COVID-19 infection.
According to the National Organization for Rare Disorders (NORD), the disease afflicts individuals in the 15 to 70 years age group. Most cases occur in individuals between 30 and 50 years of age, while the estimated mean annual incidence is 2.4 individuals per million. Prevalence rate across Europe ranges from 10.7 to 14/million, while in the US, it is 18/million. The highest prevalence rate is reported in Australia, at 22.3 cases/million.
Based on these trends, research and development to introduce novel therapeutic approaches by leading manufacturers is inclining. In 2017, the US FDA approved GlaxoSmithKline’s Nucala (mepolizumab) for treating eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US. This is the first targeted treatment approved for this rare disease. Furthermore, the approval was extended to include pediatric patients below 12 years of age in 2020.
“Increased autoimmune diseases burden is leading to widespread prevalence of severe respiratory ailments, including asthma induced by eosinophilic granulomatosis, prompting intensive research in developing potential drug candidates and a push for fast track approvals for the same,” remarks a Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=4697
Key Takeaways from Fact.MR’s Eosinophilic Granulomatosis Market Study
- By drug class, corticosteroids are expected to be the most widely consumed due to their inflammation lowering attributes
- Oral drug administration to remain the most preferred mode, intravenous administration to surge in popularity
- By distribution channel, hospital pharmacies to remain primary point of contact for availing eosinophilic granulomatosis drugs
- US to emerge as a promising market amid increasing orphan drugs designation approvals by the FDA
- Increasing regulatory approvals for self-administration for certain drugs is widening OTC exchange across the UK
- Germany & France to emerge as pioneers in rituximab (RTX) EGPA treatment
- Rising incidences of severe asthma attacks to heighten prospects for the Indian market
Eosinophilic Granulomatosis Market- Prominent Drivers
- Increasing frequencies of orphan drugs designations by key regulatory authorities driving sales of eosinophilic granulomatosis drugs
- Widening patient pool suffering from autoimmune diseases is leading to rising prevalence of EGPA, spurring heightened research
- Government initiative to rein in prevalence of autoimmune respiratory disorders acting as a major growth lever
Eosinophilic Granulomatosis Market- Key Restraints
- Prevalence of a weak healthcare infrastructure across developing regions is hampering effective adoption
- High treatment costs combined with prolonged waiting times regarding regulatory approvals likely to hinder growth
Discover more about the eosinophilic granulomatosis market with figures and data tables, along with the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/4697/eosinophilic-granulomatosis-market
Competitive Landscape
Prominent players operating in the global eosinophilic granulomatosis market are Genentech Inc. (F. Hoffmann-La Roche AG), Cephalon Inc. (Teva Pharmaceutical Industries Ltd.), Amgen Inc., Sanofi S.A., Koninklijke DSM N.V, AstraZeneca plc, Novartis International AG, GlaxoSmithKline LLC, Pharmaceuticals Holdings Corp, and Baxter Healthcare Corporation among others.
Launching new drugs to treat severe conditions is an important expansion strategy deployed by key manufacturers. For instance, Sanofi SA announced FDA approval of its Duxipent® (dupilumab) for review in children with moderate to severe asthma in March 2021. Currently, the drug is widely approved for usage across patients with uncontrolled moderate-to-severe asthma aged 12 and older.
In November 2018, AstraZeneca’s Fasenra (benralizumab) received an orphan drug designation for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). The company has been a pioneer with respect to respiratory diseases, with an ever expanding portfolio of medicines. The drug is highly effective in treating severe nasal polyposis.
More Insights on the Eosinophilic Granulomatosis Market
The research study on eosinophilic granulomatosis market by Fact.MR includes an in-depth analysis of major demand-driving factors and trends and a comprehensive evaluation of crucial aspects that are projected to carve growth. Market statistics have been elucidated based on drug class (corticosteroids, immunosuppressive agents, biologics and immunoglobulins), route of administration (oral, intravenous and intramuscular) and distribution channel (hospital pharmacies, drug stores, retail pharmacies and online pharmacies) across seven major regions (North America, Latin America, Europe, East Asia, South Asia, Oceania and Middle East & Africa).
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=4697
Explore Fact.MR’s Coverage on the Healthcare Domain
Behavioral Health Treatment Market: This Fact.MR report studies the global behavioral health treatment market for the upcoming forecast period. The primary objective of the report is to offer insights and key trends pertaining to the global behavioral health treatment market, based on the key trends, drivers and opportunities prevailing across prominent geographies and segments.
Anticoagulants Market: The study on the anticoagulants market is an exclusive report published by Fact.MR, which highlights the key parameters that are influencing the growth of the landscape. This research highlights the key trends that hold the potential to influence the growth of the anticoagulants market, along with crucial macroeconomic and microeconomic growth indicators. This insightful report offers the key dynamics, and their impact on the value chain.
Preimplantation Genetic Testing Market: The scope of Fact.MR’s report is to analyze the global preimplantation genetic testing market for the coming decade and provide readers an unbiased and accurate analysis. Medical device manufacturers, research institutes, and raw material suppliers in the global preimplantation genetic testing market can benefit from the analysis offered in this report. This report offers a comprehensive analysis, which can be of interest to leading trade magazines and medical journals pertaining to preimplantation genetic testing.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Follow Us: LinkedIn | Twitter
Market Intelligence Services: Marketngage.com
Source: Fact.MR